Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors

- Lai, Fritz, Jiang, Chen Chen, Farrelly, Margaret L., Zhang, Xu Dong, Hersey, Peter

Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors

- Lai, Fritz, Jin, Lei, Gallagher, Stuart, Mijatov, Branka, Zhang, Xu Dong, Hersey, Peter

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720

- Jiang, Chen Chen, Lai, Fritz, Thorne, Rick F., Yang, Fan, Liu, Hao, Hersey, Peter, Zhang, Xu Dong

Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells

- Liu, Yi Lun, Lai, Fritz, Jin, Lei, Zhang, Xu Dong, Wilmott, James S., Yan, Xu Guang, Liu, Xiao Ying, Luan, Qi, Guo, Su Tang, Jiang, Chen Chen, Tseng, Hsin-Yi, Scolyer, Richard A.

Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress

- Croft, Amanda, Tay, Kwang H., Zhang, Xu D., Boyd, Suzanah C., Guo, Su T., Jiang, Chen C., Lai, Fritz, Tseng, Hsin-Yi, Jin, Lei, Rizos, Helen, Hersey, Peter

RIP1 kinase is an oncogenic driver in melanoma

- Liu, Xiao Ying, Lai, Fritz, Jin, Lei, Zhang, Xu Dong, Yan, Xu Guang, Jiang, Chen Chen, Guo, Su Tang, Wang, Chun Yan, Croft, Amanda, Tseng, Hsin-Yi, Wilmott, James S., Scolyer, Richard A.

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors

- Lei, Fu Xi, Jin, Lei, Liu, Xiao Ying, Lai, Fritz, Yan, Xu Guang, Farrelly, Margaret, Guo, Su Tang, Zhao, Xin Han, Zhang, Xu Dong

RIPK1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy

- Luan, Qi, Jin, Lei, Tseng, Hsin-Yi, Zhang, Xu Dong, Jiang, Chen Chen, Tay, Kwang Hong, Lai, Fritz, Liu, Xiao Ying, Liu, Yi Lun, Guo, Su Tang, Li, Chung Ying, Yan, Xu Guang

The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance

- Wroblewski, David, Mijatov, Branka, Mohana-Kumaran, Nethia, Lai, Fritz, Gallagher, Stuart J., Haass, Nikolas K., Zhang, Xu Dong, Hersey, Peter